

SEQUENCE LISTING

<110> Gerhard , Walter
Otvos, Laszlo

<120> COMPOSITION AND METHOD FOR PREVENTING OR TREATING A VIRUS
INFECTION

<130> WSTR-0017B

<150> US 60/441,374
<151> 2003-01-16

<160> 10

<170> PatentIn version 3.1

<210> 1
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic multiple antigenic agent

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> N-terminal amino group has attached R1 which is 0 to 2 amino
acid residues, wherein said amino acid residue may be a Gly or Cys,
or a nucleic acid sequence.

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Side chain amino group has attached R2 which is a B cell
determinant, a T cell determinant, or a targeting molecule.

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Side chain amino group has attached R3 which is a B cell
determinant, a T cell determinant, or a targeting molecule.

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> "Xaa" represents 0 to 1 amino acid residue of Lys-R4, wherein R4
is a B cell determinant, a T cell determinant, or a targeting molecule.

<220>
<221> MISC_FEATURE
<222> (5)..(5)

<223> C-terminus has attached R5 group which is an amino acid, peptide, or nucleic acid sequence.

<400> 1

Lys Gly Lys Gly Xaa
1 5

<210> 2
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic multiple antigenic agent

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Mannosylated residue

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Mannosylated serine residue attached to side chain amino group

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Mannosylated serine residue attached to side chain amino group

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Mannosylated serine residue attached to side chain amino group

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> S2 peptide attached to side chain amino group

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> S1 peptide attached to side chain amino group

<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> M2e peptide attached to side chain amino group

<400> 2

Ser Lys Gly Lys Gly Lys Gly Lys Gly Lys Gly Lys Gly Ala
1 5 10

<210> 3
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic multiple antigenic agent

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Serine attached to side chain amino group

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Serine attached to side chain amino group

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> S2 peptide attached to side chain amino group

<220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> S1 peptide attached to side chain amino group

<220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> M2e peptide attached to side chain amino group

<400> 3

Lys Gly Lys Gly Lys Gly Lys Gly Lys Gly Lys Gly Ala
1 5 10

<210> 4
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic multiple antigenic agent

<220>
 <221> MISC_FEATURE
 <222> (2)..(2)
 <223> Serine residue attached to side chain

<220>
 <221> MISC_FEATURE
 <222> (4)..(4)
 <223> S2 peptide attached to side chain amino group

<220>
 <221> MISC_FEATURE
 <222> (6)..(6)
 <223> S1 peptide attached to side chain amino group

<220>
 <221> MISC_FEATURE
 <222> (8)..(8)
 <223> M2e peptide attached to side chain amino group

<220>
 <221> MISC_FEATURE
 <222> (10)..(10)
 <223> M2e peptide attached to side chain amino group

<400> 4

| | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Cys | Gly | Lys | Gly | Lys | Gly | Lys | Gly | Lys | Gly | Ala |
| 1 | | | | 5 | | | | | 10 | | |

<210> 5
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic multiple antigenic agent

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> Dimer created by disulfide linkage

<220>
 <221> MISC_FEATURE
 <222> (3)..(3)
 <223> S2 peptide attached to side chain amino group

<220>
 <221> MISC_FEATURE
 <222> (5)..(5)

<223> S1 peptide attached to side chain amino group

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> M2e peptide attached to side chain amino group

<220>

<221> MISC_FEATURE

<222> (9)..(9)

<223> M2e peptide attached to side chain amino group

<400> 5

Cys Gly Lys Gly Lys Gly Lys Gly Lys Gly Ala
1 5 10

<210> 6

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic multiple antigenic agent

<400> 6

Cys Gly Lys Gly Lys Gly Lys Ala
1 5

<210> 7

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic multiple antigenic agent

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> M2e peptide attached to side chain amino group

<220>

<221> MISC_FEATURE

<222> (5)..(5)

<223> M2e peptide attached to side chain amino group

<400> 7

Cys Gly Lys Gly Lys Gly Lys Ala
1 5

<210> 8
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic S1 peptide

<400> 8

Ser Phe Glu Arg Phe Glu Ile Phe Pro Lys Glu
 1 5 10

<210> 9
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic S2 peptide

<400> 9

His Asn Thr Asn Gly Val Thr Ala Ala Ser Ser His Glu
 1 5 10

<210> 10
 <211> 24
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic M2e peptide

<400> 10

Ser Leu Leu Thr Glu Val Glu Thr Pro Ile Arg Asn Glu Trp Gly Cys
 1 5 10 15

Arg Ser Asn Asp Ser Ser Asp Pro
 20